Neurologic Drugs : Parkinsonism
OREQU1 “Requip FC tablet” 1 mg/tab
OREQU2 “Requip FC tablet” 0.25 mg/tab
OREQU3 “Requip FC tablet” 2 mg/tab
適應症：
OREQU1, OREQU2：治療自發性帕金森氏症的徵候及症狀、治療原發性腿部躁動症（Primary restless legs syndrome）的症狀。
OREQU3：治療帕金森氏症。
Usual dose:
Parkinson’s disease:
Adult: initial, 0.25 mg tid; titrate weekly to therapeutic response; ascending dose schedule: wk 1, 0.25 mg tid; wk 2, 0.5 mg tid; wk 3, 0.75 mg tid; wk 4, 1 mg tid; after wk 4, may increase daily dosage by 1.5 mg/day on weekly basis up to 9 mg/day, then by up to 3 mg/day weekly to total dose of 24 mg/day; max. dose 24 mg/day.
Ropinirole should be gradually tapered over 7 days as follows: reduce frequency of administration from tid to bid for 4 days, then reduce to once daily for remaining 3 days.
Adverse effect:
Common: nausea, vomiting, dizziness, fatigue, headache.
Serious:orthostatic hypotension, syncope, dyskinesia, sleep attack, somnolence, hallucinations, dose related.
健保使用規範：
1.治療自發性帕金森氏症的徵候及症狀，同amantadine。(91/11/1、93/2/1、95/9/1、96/9/1、97/7/1、100/6/1、101/6/1)
2.用於治療原發性腿部躁動症時需先排除腎衰竭、鐵缺乏症及多發性神經病變，且不得與dopamine agonist及levodopa併用。（96/9/1、97/7/1）每日最大劑量為4mg。（97/7/1）